Screener
Agios Pharmaceuticals AGIO Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
FAQ
- What is Agios Pharmaceuticals's accrued expenses?
- Agios Pharmaceuticals (AGIO) reported accrued expenses of $14.75M in Q2 2026.
- How has Agios Pharmaceuticals's accrued expenses changed year-over-year?
- Agios Pharmaceuticals's accrued expenses decreased by 3.7% year-over-year, from $15.32M to $14.75M.
- What is the long-term trend for Agios Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's accrued expenses has grown at a -5.4% compound annual growth rate (CAGR), from $60.14M to $45.46M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Agios Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude